Coronavirus information from UCLA and UCLA Health

Magnify

The Next Generation Incubator

Pelage Pharmaceuticals, Inc. is a biotechnology company developing novel drugs to promote hair health.

Market:

Currently, 400 million people, both men and women, suffer from Alopecia worldwide. There are only two FDA-approved medications for treating non-scarring Alopecia, Propecia and Rogaine (Minoxidil). Propecia is associated with adverse side effects and neither drug is very effective. More than $7 billion is being spent on hair loss treatments annually.

Technology:

Pelage’s proprietary small molecules are the first to target hair follicle stem cell metabolism causing their activation.

Advantages:

  • Activates quiescent hair follicle stem cells
  • Small molecules access the hair follicles when applies to the scalp
  • No need for implants, injections or oral treatments

Patents:

  • Pelage has licensed rights from the University of California to pending patent applications covering the technology.

Development Stage:

  • Pre-clinical

Select Publications:

Contact:

Email: info@pelagepharma.com